Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease

Ageing Res Rev. 2023 Mar:85:101815. doi: 10.1016/j.arr.2022.101815. Epub 2022 Dec 16.

Abstract

Alzheimer's disease (AD) is a multivariate and diversified disease and affects the most sensitive areas of the brain, the cerebral cortex, and the hippocampus. AD is a progressive age-related neurodegenerative disease most often associated with memory deficits and cognition that get more worsen over time. The central theory on the pathophysiological hallmark features of AD is characterized by the accumulation of amyloid β (Aβ) peptides, also associated with tau proteins (τ) dysfunctioning which leads to distorted microtubular structure, affects the cholinergic system, and mitochondrial biogenesis. This review emphasizes how simple it is to find novel treatments for AD and focuses on several recently developed medications through repurposing that can speed up traditional drug development.

Keywords: Alzheimer’s disease; Molecular targets; Neurodegenerative disorder; Neuroprotection; Repurposed drugs.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / metabolism
  • Drug Repositioning
  • Humans
  • Neurodegenerative Diseases*
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • tau Proteins